The Lineup: Novel Products Awaiting Action In 2011
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
The Return Of Big Pharma? 2011 Novel Approvals Could Show Payoff Of Licensing And Acquisition Strategies
Familiar faces and familiar indications dominate the slate of novel drug candidates in line for FDA action in 2011, a change from recent years.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.